HYPR Surges 31% on AI-Medical Breakthrough—What’s Next?

Summary
• Hyperfine (HYPR) rockets 31.25% intraday to $1.05, shattering its 52-week low of $0.53
• First commercial sales of AI-powered Swoop MRI system drive optimism
• Options market surges with 186.52% implied volatility on August 15 $1 call
• RSI hits 63.14 as bulls push price above 200-day average of $0.89

HYPR’s 31% intraday rally has turned heads in the medical tech space, fueled by historic commercial sales of its FDA-cleared Swoop® system. The stock’s surge defies a weak Medical Equipment sector, with Medtronic (MDT) down 0.44%. Traders are scrambling to position for a potential breakout as technicals and options activity suggest short-term bullish momentum.

FDA-Cleared AI MRI Drives Commercial Momentum
The 31.25% price surge stems from Hyperfine’s landmark sale of its next-generation Swoop® system to two top-tier U.S. hospitals. The AI-powered portable MRI, cleared by the FDA, now enters clinical deployment in ICU and emergency departments. CEO Maria Sainz emphasized the system’s ‘commercial readiness’ and ‘diagnostic-level clarity,’ with the Optive AI software enhancing image resolution and acquisition speed. This marks the first major revenue-generating step after months of regulatory hurdles, validating the company’s $1.96 GF Value estimate and analysts’ $1.06 average target.

HYPR Defies Medical Equipment Sector Weakness as MDT Slides
While the broader Medical Equipment sector underperforms, with Medtronic (MDT) down 0.44%, Hyperfine’s stock has surged on product-driven optimism. The Swoop® system’s FDA clearance and commercial deployment create a unique catalyst absent in sector peers. This divergence highlights HYPR’s speculative appeal as a disruptive innovator versus MDT’s established but slower-moving business model.

Capitalizing on HYPR’s Breakout: ETFs and Options Playbook
• 200-day MA: $0.89 (bullish crossover)
• RSI: 63.14 (neutral-to-bullish)
• MACD: 0.0219 (bullish histogram)
• Bollinger Bands: Price ($1.05) above upper band ($0.83)
• Support/Resistance: 30D range ($0.796–$0.800), 200D range ($0.988–$1.011)

HYPR’s technicals signal a breakout setup, with price above key moving averages and RSI in constructive territory. The $1.05 level tests 200D resistance, with a 1.9% upside to 52-week high ($1.90). Traders should watch for a close above $1.09 (intraday high) to confirm momentum. Options activity intensifies, with the HYPR20250815C1 ($1 call, 186.52% IV) and HYPR20251017C1 ($1 call, 299.61% IV) showing high leverage and liquidity. The August 15 $1 call offers 4.24% leverage with a delta of 0.65, ideal for short-term plays. For longer-term exposure, the October 17 $1 call (1.77% leverage, 0.79 delta) balances time decay and gamma sensitivity. Aggressive bulls may consider HYPR20250815C1 into a bounce above $1.09.

Backtest Hyperfine Stock Performance
The 31% intraday surge in HYPR resulted in mixed short-to-medium-term performance. While the 3-day win rate was high at 40.38%, the returns over 10 and 30 days were negative at -0.33% and -0.32%, respectively. The maximum return during the backtest period was only 0.73%, which occurred on day 26, indicating that the optimal timing for a positive outcome was late in the 3-day period.

HYPR’s AI Breakthrough: Time to Ride the Wave or Wait for Clarity?
HYPR’s 31% rally reflects a pivotal shift in market sentiment, driven by regulatory validation and commercial traction. The stock’s technicals and options activity suggest a short-term bullish bias, but investors must balance optimism with caution. With Medtronic (MDT) down 0.44%, sector divergence underscores HYPR’s speculative edge. Key levels to watch: $1.09 (intraday high) and $0.988 (200D support). For those seeking leverage, the HYPR20250815C1 offers aggressive upside potential. Immediate action: Buy the August 15 $1 call for a 4.24% leveraged play if $1.09 breaks.